Business Context and Reporting Period
This Form 6-K filing by MDxHealth SA covers the month of February 2023. The Company, a foreign private issuer incorporated in Belgium, reported the completion of a public offering of American Depositary Shares (ADSs) and a corresponding capital increase.
Key Financial Metrics
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for the period. The primary financial data relates to the capital raise:
- Shares Issued: 10,000,000 ADSs (each representing 10 ordinary shares).
- Over-Allotment Option: Underwriters granted an option to purchase up to an additional 1,500,000 ADSs.
- Net Proceeds: Approximately $37.0 million, or $42.6 million if the over-allotment option is exercised in full.
- Capital Increase: 100,000,000 new ordinary shares authorized via amendment to the Articles of Association.
Material Changes
The material change reported is the successful closing of the Offering on February 7, 2023. This event resulted in a significant increase in the Company's share capital and cash liquidity, subject to the deduction of underwriting commissions and offering expenses.
Outlook, Risks, and Management Commentary
The filing confirms the execution of an Underwriting Agreement with Cowen and Company, LLC and William Blair & Company, L.L.C. The proceeds are intended to support the Company's operations, though specific allocation details are not provided in this summary text. The filing incorporates by reference the Underwriting Agreement and legal opinions regarding the legality of the issuance.
Investor Verification Checklist
- Verify the final exercise status of the 1,500,000 ADS over-allotment option to confirm total proceeds.
- Review the attached press releases (Exhibits 99.1 and 99.2) for specific details on the use of proceeds.
- Confirm the updated share count and dilution impact following the issuance of 100,000,000 new shares.
- Check subsequent filings for any updates on the Company's cash position post-offering.